Oxford BioDynamics has developed a platform for discovering, evaluating, validating, and monitoring a unique class of epigenetic biomarkers.
The effort, which relied on Oxford BioDynamics' EpiSwitch platform, resulted in an assay that researchers believe could be developed into a test to guide therapy selection for patients.
The partners will perform blood-based tests on Oxford's Episwitch platform to monitor epigenetic changes of athletes with concussions.
The British company has announced the results of two studies showcasing the ability of its EpiSwitch platform to diagnose and stage breast cancer and ALS patients.
Nova Satra said it will use the EpiSwitch technology to develop and commercialize non-invasive breast cancer testing across 13 territories in Asia.
The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.
Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.
In Science this week: in vitro generation of human reproductive cells, and more.
Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.